Dr. Timothy Cloughesy introduces the program focusing on managing IDH-mutant gliomas after surgery, joined by Dr. Ugur Sener from Mayo Clinic. The discussion establishes IDH-mutant gliomas as a unique disease entity distinct from IDH-wild-type glioblastomas.
Dr. Cloughesy details the evolution from phase 1 studies observing gradual tumor shrinkage in non-enhancing tumors to the pivotal INDIGO phase 3 trial design. The study specifically enrolled patients with measurable tumors who experienced growth trajectories that subsequently changed during treatment, convincing investigators of meaningful drug activity.
